Cue Biopharma, Inc.
- CUE
- NASDAQ
- Biotechnology
- Immune-Modulating Biologics
- Oncology/Autoimmune Therapy
$16.08
Today −3.77%Quote Oct 19, 2026, 08:00 PM UTC
−56.60%over the last month
Max drawdown −56.6%From 1-month high −56.6%3 months −51.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Cue Biopharma
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
29
Founded
2014
Market value
$116.8M
Quote Oct 19
Analyst target
$83.00
+416.2% from here
Floor
$12.50
22.3% below price
Resistance
$20.75
29.0% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CUEPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free